ReBio

ReBio is featured this month by Kuopio Health... read on to hear more about us and meet some of the team. #finland #biotech #kuopiohealth https://lnkd.in/dHT82MV9

✨Olemme innoissamme, kun saamme esitellä jälleen uuden ekosysteemimme jäsenen! Tervetuloa mukaan ReBio Technologies Oy. ReBio Technologies Oy, on vuonna 2015 perustettu yritys, joka tuo uusia, pitkäkestoisia ratkaisuja silmäsairauksiin tarkoitettujen lääkkeiden annosteluun. ReBion teknologia tarjoaa turvallisen, tehokkaan ja potilasystävällisen annostelumuodon ja ratkoo silmäsairauksien hoidon haasteita. Harri Jukarainen Voit lukea jäsenesittelyn täältä: https://lnkd.in/gZsbQDJM #innovaatiot #silmäsairaudet #kuopiohealth

Thank you Stockholm and EBD Group for an excellent gathering for BIO-Europe. Great memories, new connections and exciting opportunities we could only create together! #BIOEurope #BusinessTurku #BusinessFinland Vinod Vijayakumar Kristof Kunzmann Alexander

Looking forward to meeting our partners and collaborators at BioEurope 2024 in a few short weeks! You will find us on the floor along with other biotech and medtech businesses from Finland at the Business Turku booth. See you in Stockholm! #bioeurope #businessturku #biotech #finland #turku

Our team is looking forward to LSX Nordic in a few weeks, presenting with our current partners and making new connections. Hope to see you 8-9 October in Cph! LSX - partnering for Life Science eXecutives #biotech #partnering #ophthalmology #glaucoma

ReBio Pharma joins the Kuopio Health network - fostering open innovation and creating opportunities with healthcare businesses in the Kuopio region. We are excited to be alongside other technology innovators in the field and look forward to future collaborations with new partners. #kuopio #medtech #innovation #KuopioHealth #PharmaDevelopment https://lnkd.in/dbzjaRFc

As we wrap up #HealthyVisionMonth, recognized by National Eye Institute (NEI), a division of the The National Institutes of Health, ReBio Pharma acknowledges the millions of people living with #glaucoma and other eye diseases around the world, and encourages everyone to take care of their eye health! We know eye exams are so important but are not always affordable. That’s why we wanted to share NEI’s resources for helping you access low-cost eye care. This resource page shares information on many US-based charities and other organizations that may be able to help, including VSP Vision, Lions Club International, the American Glaucoma Society, the National Federation of the Blind, and more. Resources: https://lnkd.in/ervGN9eT The NEI’s mission – to eliminate vision loss and improve quality of life through vision research – is one we celebrate and share wholeheartedly. #EyeHealthEducation #drugdevelopment #ReBio #lowvision #blindness #visuallyimpared

ReBio Pharma was so excited to attend #ARVO2024 this year. In our first-ever public data presentation, we shared results of a safety, tolerability, and pharmacokinetics study for our lead investigational product for #glaucoma, RBLP. We believe our drug delivery platform, SiSu®, has the potential to transform disease management for a broad range of indications and represents a step-change in versatility over currently available sustained release methods. Learn more here: https://lnkd.in/eJbB-Rw3. #investors #eyehealth #visionloss #biotech

ReBio Pharma to Deliver Poster Presentation at Upcoming Association for Research in Vision and Ophthalmology Annual Meeting ReBio Pharma will be delivering a poster presentation at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 5-9 in Seattle, Washington, USA.  The poster highlights pre-clinical pharmacokinetics, safety, and tolerability data that indicates the ability to safely control intravitreal sustained release for varying durations via the company’s proprietary SiSu® technology platform. SiSu® is a phase-inverting anhydrous liquid polymer formulation that creates a semi-solid in-situ forming implant (ISFI) when injected into an aqueous environment. SiSu® is designed to steadily release effective levels of therapeutics while safely dissolving once drug release is completed, and can be tuned to the drug, indication, and duration of release required. ReBio Pharma has several investigational therapeutics in its pipeline intended for delivery via the SiSu® technology platform, the first of which is RBLP, a twice-yearly intravitreally administered formulation of latanoprost for the treatment of mild-to-moderate primary open-angle glaucoma.  “We are excited to attend ARVO this year and present the results of this safety, tolerability, and pharmacokinetics study for our lead product for glaucoma, RBLP,” says Vinod Vijayakumar, CEO of ReBio Pharma. “This marks an important milestone for ReBio Pharma, as it is our first-ever public data presentation. We are looking forward to sharing the important work we’re doing with the broader ophthalmology community. We believe our drug delivery platform, SiSu®, has the potential to transform disease management for a broad range of indications and represents a step-change in versatility over currently available sustained release methods.”  Discover more at https://lnkd.in/dXf87_2T #ophthalmology #glaucoma #lifesciences #biotechnology #healthcareinnovation